Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 107Lymphoma 48Lymphoma, Non-Hodgkin 44Hodgkin Disease 44Leukemia, Myeloid, Acute 41Myelodysplastic Syndromes 40Leukemia 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 26Neoplasms, Plasma Cell 25Lymphoma, Large B-Cell, Diffuse 24Lymphoma, Follicular 24Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Myeloproliferative Disorders 16Recurrence 14Immunoglobulin Light-chain Amyloidosis 14Congenital Abnormalities 13Primary Myelofibrosis 12Lymphoma, Large-Cell, Immunoblastic 12Leukemia, Myeloid, Accelerated Phase 12Hematologic Neoplasms 12Waldenstrom Macroglobulinemia 10Lymphoma, T-Cell, Cutaneous 10Leukemia, Myelomonocytic, Juvenile 10Leukemia, Myelomonocytic, Chronic 10Leukemia, Myeloid, Chronic-Phase 10Dendritic Cell Sarcoma, Interdigitating 10

Interventions

liposomal doxorubicin 1Widowhood 1Videotape Recording 1Surveys and Questionnaires 1Melphalan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Patient Participation × Melphalan × Clear all
NCT00985907 2020-06-17

DMV

University of California, San Francisco

Phase 1/2 Terminated
13 enrolled 8 charts
Plasma cell

Multiple Myeloma, Patient Participation, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡